Physician profile
Navin Verma
NPI 1346299625
$6,954.10
in general payments reported to CMS, 2019-2025
8 companies · $6,577 in 2025
The $6,577 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.94 · 2020: $41.89 · 2023: $93.12 · 2024: $163 · 2025: $6,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,784 · Food and Beverage: $648 · Travel and Lodging: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,783.87 |
| Food and Beverage | $648.00 |
| Travel and Lodging | $401.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $4,332.85 | 2025 | Filspari |
| Calliditas Therapeutics US INC. | $2,183.87 | 2025 | Tarpeyo |
| Emd Serono, INC. | $102.74 | 2019-2020 | |
| Baxter Healthcare | $93.17 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $93.12 | 2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $87.92 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $35.00 | 2025 | |
| Biogen, INC. | $25.43 | 2025 | Leqembi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.